approval · primary record
BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM
FDA · NDA · 2026-08-27
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-08-27 |
| Approval events | 1 |
| Brand | BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) |
| Sponsor | GILEAD SCIENCES INC |
| Route | ORAL |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-08-27 | FDA | NDA | BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) | GILEAD SCIENCES INC | ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:10.162Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:bictegravir-sodium-lenacapavir-sodium
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Bictegravir Sodium, Lenacapavir Sodium · compound